TG Therapeutics Q4 revenue rises on BRIUMVI sales, but profit dips

Reuters02-26
TG <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 revenue rises on BRIUMVI sales, but profit dips

Overview

  • Biotechnology firm's Q4 product revenue grew yr/yr, driven by BRIUMVI sales

  • Net income for Q4 was $23 mln, slight dip yr/yr

  • Company completed $100 mln share repurchase program, announced new $100 mln authorization

Outlook

  • TG Therapeutics targets 2026 global revenue of $875-$900 mln

  • Company expects Q1 2026 BRIUMVI U.S. revenue of $185-$190 mln

  • TG Therapeutics anticipates $350 mln in 2026 operating expenses excluding non-cash compensation

Result Drivers

  • BRIUMVI SALES GROWTH - BRIUMVI U.S. net product revenue grew 20% qtr/qtr and 92% yr/yr, driven by increased adoption and global expansion

  • GLOBAL EXPANSION - BRIUMVI commercialization expanded outside U.S. with approvals in EU, UK, Switzerland, Australia, Kuwait, and UAE

  • CLINICAL ADVANCEMENTS - Co advanced late-stage clinical programs, including subcutaneous ublituximab and ENHANCE trial for new dosing regimen

Company press release: ID:nGNX1YL6Ky

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Product Revenue

$189.11 mln

Q4 Net Income

$23.04 mln

Q4 Operating Income

$50.49 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for TG Therapeutics Inc is $48.00, about 61.8% above its February 25 closing price of $29.66

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment